Project Grant R37CA288506
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $546K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a Phase 1/2 clinical trial to evaluate the combination of PEP-CMV vaccine and nivolumab immunotherapy for the treatment of pediatric brain cancers such as diffuse midline glioma, high-grade glioma, medulloblastoma, and ependymoma. The $553,167 award to Washington University will fund research to assess the safety, feasibility, and potential efficacy of this novel immunotherapeutic...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394), awarded a $244,839 project grant to the University of Virginia. The grant aims to investigate the potential of using magnetic resonance imaging-guided focused ultrasound (MRGFUS) to enhance the delivery and persistence of chimeric antigen receptor (CAR) T cell therapy for pediatric medulloblastoma, a common and challenging brain cancer in children. Under a sub-award,...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $167,584.00 to the University of California, San Diego (UCSD) to generate human induced pluripotent stem cell (hiPSC) models of atypical teratoid rhabdoid tumors (ATRTs) - an aggressive form of pediatric brain cancer. The primary goals are to investigate the cell of origin for ATRTs and identify potential therapeutic vulnerabilities. Specifically, the award supports research to derive...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...